首页 > 最新文献

Chest最新文献

英文 中文
Perspectives of clinicians on the value of the Get to Know Me board in the Intensive Care Unit. 临床医生对重症监护室 "认识我 "板块价值的看法。
IF 9.6 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-10-18 DOI: 10.1016/j.chest.2024.10.016
Sumera R Ahmad,Lori Rhudy,Amelia K Barwise,Mahmut C Ozkan,Ognjen Gajic,Lioudmila V Karnatovskaia
BACKGROUNDCritical illness can render patients at heightened risk of anonymity, loss of dignity and dehumanization. As dehumanization results in significant patient distress, it is imperative to find ways to humanize care in the ICU. A Get to Know Me Board (GTKMB) is a personal patient profile designed to bring the patient from anonymity, yet its widespread adoption has been challenging.RESEARCH QUESTIONIdentify perspectives of ICU clinicians on the value of the GTKMB in caring for ICU patients.STUDY DESIGN AND METHODSThis qualitative study used focus groups conducted via videoconference. We recruited stakeholders from multiprofessional teams across different ICU settings at a large U.S. quaternary care center. Thematic content analysis approach was performed to identify key themes and concepts.RESULTSWe interviewed 38 participants in 6 focus groups including 10 nurses, 7 physicians, 6 advanced practice providers, 5 rehabilitation therapists, a respiratory therapist, and a social worker. Themes highlighted the role of the GTKMB in multiple domains including a) humanizing care of the critically ill, b) fostering communication, c) connecting with families and d) guiding and facilitating care processes. Several sub- themes were identified for each category.INTERPRETATIONThe GTKMB was considered important in fostering humanized caring in the ICU by diverse members of an interprofessional ICU team, helping to facilitate communication, establish family connection, and guide care.
背景重症患者可能面临匿名、丧失尊严和非人化的更大风险。由于非人化会导致患者痛苦不堪,因此必须设法使重症监护病房的护理人性化。研究问题确定重症监护室临床医生对 GTKMB 在重症监护室患者护理中的价值的看法。我们招募了来自美国一家大型四级医疗中心不同 ICU 设置的多专业团队的利益相关者。我们在 6 个焦点小组中采访了 38 名参与者,其中包括 10 名护士、7 名医生、6 名高级医疗服务提供者、5 名康复治疗师、1 名呼吸治疗师和 1 名社会工作者。这些主题强调了 GTKMB 在多个领域的作用,包括 a) 为重症患者提供人性化护理;b) 促进沟通;c) 与家属建立联系;d) 指导和促进护理流程。GTKMB在重症监护病房的人性化护理方面发挥着重要作用,它由重症监护病房跨专业团队的不同成员组成,有助于促进沟通、建立家庭联系和指导护理。
{"title":"Perspectives of clinicians on the value of the Get to Know Me board in the Intensive Care Unit.","authors":"Sumera R Ahmad,Lori Rhudy,Amelia K Barwise,Mahmut C Ozkan,Ognjen Gajic,Lioudmila V Karnatovskaia","doi":"10.1016/j.chest.2024.10.016","DOIUrl":"https://doi.org/10.1016/j.chest.2024.10.016","url":null,"abstract":"BACKGROUNDCritical illness can render patients at heightened risk of anonymity, loss of dignity and dehumanization. As dehumanization results in significant patient distress, it is imperative to find ways to humanize care in the ICU. A Get to Know Me Board (GTKMB) is a personal patient profile designed to bring the patient from anonymity, yet its widespread adoption has been challenging.RESEARCH QUESTIONIdentify perspectives of ICU clinicians on the value of the GTKMB in caring for ICU patients.STUDY DESIGN AND METHODSThis qualitative study used focus groups conducted via videoconference. We recruited stakeholders from multiprofessional teams across different ICU settings at a large U.S. quaternary care center. Thematic content analysis approach was performed to identify key themes and concepts.RESULTSWe interviewed 38 participants in 6 focus groups including 10 nurses, 7 physicians, 6 advanced practice providers, 5 rehabilitation therapists, a respiratory therapist, and a social worker. Themes highlighted the role of the GTKMB in multiple domains including a) humanizing care of the critically ill, b) fostering communication, c) connecting with families and d) guiding and facilitating care processes. Several sub- themes were identified for each category.INTERPRETATIONThe GTKMB was considered important in fostering humanized caring in the ICU by diverse members of an interprofessional ICU team, helping to facilitate communication, establish family connection, and guide care.","PeriodicalId":9782,"journal":{"name":"Chest","volume":"1 1","pages":""},"PeriodicalIF":9.6,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142486316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Comparison of GOLD and STAR Severity Stages in Individuals with Chronic Obstructive Pulmonary Disease Undergoing Pulmonary Rehabilitation. 接受肺康复治疗的慢性阻塞性肺病患者的 GOLD 和 STAR 严重程度分级比较。
IF 9.6 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-10-18 DOI: 10.1016/j.chest.2024.10.013
Pasquale Ambrosino,Michele Vitacca,Giuseppina Marcuccio,Antonio Spanevello,Nicolino Ambrosino,Mauro Maniscalco
BACKGROUNDAlongside the recognized Global Initiative for Obstructive Lung Disease (GOLD) classification, the STaging of Airflow obstruction by Ratio (STAR) severity scheme has been proposed for categorizing chronic obstructive pulmonary disease (COPD).STUDY QUESTIONWhat is the agreement and utility of the GOLD and STAR classifications in severe COPD patients entering the rehabilitation setting?STUDY DESIGN AND METHODSMedical records were reviewed in this multicenter retrospective study, examining key functional variables and their changes in a large cohort of COPD patients undergoing pulmonary rehabilitation (PR).RESULTSA total of 1,516 participants (33.7% females, median age 72.0 years) were included in the analysis. Compared to GOLD, the use of the STAR classification resulted in a different disease severity category for 53.4% of patients. An unweighted Cohen's κ of 0.25 and a Bangdiwala B value of 0.24 revealed a fair agreement between the two classifications. Higher weighted agreement measures (0.47 and 0.78, respectively) suggested that discrepancies between the classifications mainly occurred for contiguous stages. GOLD demonstrated superior discrimination between stages for chronic respiratory failure, while STAR exhibited better performance in detecting hyperinflation. In terms of their application within PR settings, GOLD exhibited superior performance compared to STAR in identifying the minimal clinically important difference (MCID) in 6-minute walking distance and modified Medical Research Council (mMRC) score. Accordingly, GOLD but not STAR acted as an independent predictor for achieving a MCID in mMRC (OR: 1.48; 95% CI: 1.12-1.94; P=0.005) and also independently predicted changes in Braden score (β=0.154; P=0.004).INTERPRETATIONSTAR shows a more uniform gradation of disease severity and enhanced performance in detecting hyperinflation but our preliminary findings do not endorse its utilization in the rehabilitation setting.
背景除了公认的全球阻塞性肺病倡议(GOLD)分类外,还提出了按比例对气流阻塞(STAR)严重程度进行分级的方案,用于对慢性阻塞性肺病(COPD)进行分类。研究问题在进入康复环境的重度 COPD 患者中,GOLD 和 STAR 分类的一致性和实用性如何?研究设计和方法在这项多中心回顾性研究中回顾了医疗记录,检查了一大批接受肺康复(PR)治疗的 COPD 患者的主要功能变量及其变化。与 GOLD 相比,使用 STAR 分级法可使 53.4% 的患者获得不同的疾病严重程度类别。非加权科恩κ值为0.25,Bangdiwala B值为0.24,显示两种分类方法的一致性尚可。较高的加权一致度(分别为 0.47 和 0.78)表明,分类之间的差异主要发生在连续的分期上。GOLD 对慢性呼吸衰竭的分期显示出更高的区分度,而 STAR 在检测过度充气方面表现出更好的性能。在 PR 环境中的应用方面,GOLD 与 STAR 相比,在识别 6 分钟步行距离和改良医学研究委员会(mMRC)评分的最小临床重要性差异(MCID)方面表现更佳。因此,GOLD 而非 STAR 是实现 mMRC MCID 的独立预测因子(OR:1.48;95% CI:1.12-1.94;P=0.005),而且还能独立预测 Braden 评分的变化(β=0.154;P=0.004)。
{"title":"A Comparison of GOLD and STAR Severity Stages in Individuals with Chronic Obstructive Pulmonary Disease Undergoing Pulmonary Rehabilitation.","authors":"Pasquale Ambrosino,Michele Vitacca,Giuseppina Marcuccio,Antonio Spanevello,Nicolino Ambrosino,Mauro Maniscalco","doi":"10.1016/j.chest.2024.10.013","DOIUrl":"https://doi.org/10.1016/j.chest.2024.10.013","url":null,"abstract":"BACKGROUNDAlongside the recognized Global Initiative for Obstructive Lung Disease (GOLD) classification, the STaging of Airflow obstruction by Ratio (STAR) severity scheme has been proposed for categorizing chronic obstructive pulmonary disease (COPD).STUDY QUESTIONWhat is the agreement and utility of the GOLD and STAR classifications in severe COPD patients entering the rehabilitation setting?STUDY DESIGN AND METHODSMedical records were reviewed in this multicenter retrospective study, examining key functional variables and their changes in a large cohort of COPD patients undergoing pulmonary rehabilitation (PR).RESULTSA total of 1,516 participants (33.7% females, median age 72.0 years) were included in the analysis. Compared to GOLD, the use of the STAR classification resulted in a different disease severity category for 53.4% of patients. An unweighted Cohen's κ of 0.25 and a Bangdiwala B value of 0.24 revealed a fair agreement between the two classifications. Higher weighted agreement measures (0.47 and 0.78, respectively) suggested that discrepancies between the classifications mainly occurred for contiguous stages. GOLD demonstrated superior discrimination between stages for chronic respiratory failure, while STAR exhibited better performance in detecting hyperinflation. In terms of their application within PR settings, GOLD exhibited superior performance compared to STAR in identifying the minimal clinically important difference (MCID) in 6-minute walking distance and modified Medical Research Council (mMRC) score. Accordingly, GOLD but not STAR acted as an independent predictor for achieving a MCID in mMRC (OR: 1.48; 95% CI: 1.12-1.94; P=0.005) and also independently predicted changes in Braden score (β=0.154; P=0.004).INTERPRETATIONSTAR shows a more uniform gradation of disease severity and enhanced performance in detecting hyperinflation but our preliminary findings do not endorse its utilization in the rehabilitation setting.","PeriodicalId":9782,"journal":{"name":"Chest","volume":"29 1","pages":""},"PeriodicalIF":9.6,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142486352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Perioperative Pulmonary Artery Catheter Use on Clinical Outcomes Following Cardiac Surgery: A Nationwide Cohort Study. 围手术期使用肺动脉导管对心脏手术临床结果的影响:全国队列研究
IF 9.6 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-10-17 DOI: 10.1016/j.chest.2024.10.008
Jae-Woo Ju,Jaeyeon Chung,Gang Heo,Youn Joung Cho,Yunseok Jeon,Karam Nam
BACKGROUNDEvidence on the effectiveness of pulmonary artery catheters (PACs) in cardiac surgery is scarce.RESEARCH QUESTIONDoes perioperative PAC use decrease on 1-year all-cause mortality in patients undergoing cardiac surgery?STUDY DESIGN AND METHODSThis nationwide, population-based cohort study included all adult patients who underwent cardiac surgery in Korea between January 2011 and December 2020 using a Korean health insurance claim database. We compared the primary outcome, the risk of 1-year all-cause mortality, between patients with and without perioperative use of PACs (PAC and no-PAC groups, respectively) using logistic regression analysis after stabilized inverse probability of treatment weighting. A subgroup analysis was performed to determine whether the association varied according to the type of cardiac surgery and institutional case volume.RESULTSA total of 61,405 patients were analyzed. The PAC group had a significantly lower risk of 1-year all-cause mortality than that in the no-PAC group (adjusted odds ratio [OR], 0.81; 95% confidence interval [CI], 0.76-0.86). In the subgroup analysis, both the type of cardiac surgery and institutional case volume were identified as significant modifiers (all P for interaction<0.001). Specifically, the PAC group had a significantly lower risk of 1-year all-cause mortality following isolated off-pump coronary artery bypass grafting (adjusted OR, 0.54; 95% CI, 0.48-0.61) compared to the no-PAC group. PAC use was associated with a significant reduction in the risk of 1-year all-cause mortality in the lowest-case volume centers (<100 cases/year; OR, 0.70; 95% CI, 0.65-0.76).INTERPRETATIONPerioperative use of PACs was associated with a significant reduction in the risk of postoperative 1-year all-cause mortality. This association was predominantly driven by patients who underwent off-pump coronary artery bypass grafting and those who underwent cardiac surgery in less experienced centers.
研究问题围手术期使用肺动脉导管(PAC)是否会降低心脏手术患者的 1 年全因死亡率?研究设计和方法这项基于人群的全国性队列研究利用韩国健康保险索赔数据库纳入了 2011 年 1 月至 2020 年 12 月期间在韩国接受心脏手术的所有成年患者。我们对主要结果--围术期使用和未使用 PAC 的患者(分别为使用 PAC 组和未使用 PAC 组)的 1 年全因死亡率风险进行了比较,采用的是经过稳定的逆治疗概率加权后的逻辑回归分析。结果共分析了 61,405 例患者。PAC组的1年全因死亡风险明显低于无PAC组(调整后的几率比[OR]为0.81;95%置信区间[CI]为0.76-0.86)。在亚组分析中,心脏手术类型和机构病例量都被认为是显著的调节因素(交互作用的 P 均<0.001)。具体来说,与无 PAC 组相比,PAC 组在进行孤立的非泵冠状动脉旁路移植术后 1 年全因死亡风险明显降低(调整 OR,0.54;95% CI,0.48-0.61)。在病例量最低的中心(<100 例/年;OR,0.70;95% CI,0.65-0.76),使用 PAC 可显著降低术后 1 年全因死亡的风险。这种关联主要是由接受非泵冠状动脉旁路移植术的患者和在经验较少的中心接受心脏手术的患者造成的。
{"title":"Impact of Perioperative Pulmonary Artery Catheter Use on Clinical Outcomes Following Cardiac Surgery: A Nationwide Cohort Study.","authors":"Jae-Woo Ju,Jaeyeon Chung,Gang Heo,Youn Joung Cho,Yunseok Jeon,Karam Nam","doi":"10.1016/j.chest.2024.10.008","DOIUrl":"https://doi.org/10.1016/j.chest.2024.10.008","url":null,"abstract":"BACKGROUNDEvidence on the effectiveness of pulmonary artery catheters (PACs) in cardiac surgery is scarce.RESEARCH QUESTIONDoes perioperative PAC use decrease on 1-year all-cause mortality in patients undergoing cardiac surgery?STUDY DESIGN AND METHODSThis nationwide, population-based cohort study included all adult patients who underwent cardiac surgery in Korea between January 2011 and December 2020 using a Korean health insurance claim database. We compared the primary outcome, the risk of 1-year all-cause mortality, between patients with and without perioperative use of PACs (PAC and no-PAC groups, respectively) using logistic regression analysis after stabilized inverse probability of treatment weighting. A subgroup analysis was performed to determine whether the association varied according to the type of cardiac surgery and institutional case volume.RESULTSA total of 61,405 patients were analyzed. The PAC group had a significantly lower risk of 1-year all-cause mortality than that in the no-PAC group (adjusted odds ratio [OR], 0.81; 95% confidence interval [CI], 0.76-0.86). In the subgroup analysis, both the type of cardiac surgery and institutional case volume were identified as significant modifiers (all P for interaction<0.001). Specifically, the PAC group had a significantly lower risk of 1-year all-cause mortality following isolated off-pump coronary artery bypass grafting (adjusted OR, 0.54; 95% CI, 0.48-0.61) compared to the no-PAC group. PAC use was associated with a significant reduction in the risk of 1-year all-cause mortality in the lowest-case volume centers (<100 cases/year; OR, 0.70; 95% CI, 0.65-0.76).INTERPRETATIONPerioperative use of PACs was associated with a significant reduction in the risk of postoperative 1-year all-cause mortality. This association was predominantly driven by patients who underwent off-pump coronary artery bypass grafting and those who underwent cardiac surgery in less experienced centers.","PeriodicalId":9782,"journal":{"name":"Chest","volume":"67 1","pages":""},"PeriodicalIF":9.6,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142451799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative effectiveness of albumin versus no albumin on renal replacement therapy and mortality in patients with septic shock and renal impairment. 白蛋白与无白蛋白对脓毒性休克和肾功能受损患者肾脏替代治疗和死亡率的比较效果。
IF 9.6 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-10-17 DOI: 10.1016/j.chest.2024.10.012
Asad E Patanwala,Alexander H Flannery,Hemalkumar B Mehta,Thomas E Hills,Colin J McArthur,Brian L Erstad
BACKGROUNDAlbumin infusions may be renally protective or harmful in patients with septic shock who have kidney impairment. This can affect the need for renal replacement therapy (RRT) and in-hospital mortality.RESEARCH QUESTIONDoes the early use of albumin mitigate the need for RRT or in-hospital mortality in patients with septic shock and kidney impairment on hospital admission.STUDY DESIGN AND METHODSThis was a retrospective, multicenter, inverse probability-of-treatment weighted cohort study conducted in 220 geographically diverse community and teaching hospitals across the U.S. Adult patients were included if they had septic shock and kidney impairment on hospital admission. Patients were categorized as those who received albumin (within 24h of admission) or no albumin during hospitalization. Proportion of patients with RRT or in-hospital mortality were compared between groups.RESULTSOf the 9988 patients included in the final cohort, 7929 did not receive albumin and 2059 received albumin. Patients had a mean (SD) age of 67.8 years (14.8), 46.3% were female, and mean (SD) eGFR was 32 (12) ml/min/1.73m2 on the day of admission. In the weighted cohort, the composite outcome of RRT or in-hospital mortality occurred in 33.8% without albumin and 39.7% with albumin (OR 1.29, 95% CI 1.14 - 1.47, p<0.001). There was no significant difference with 5% albumin (OR 1.07, 95% CI 0.84 - 1.37), but there was a significantly increased risk with 25% albumin (OR 1.43, 95% CI 1.16 - 1.76).INTERPRETATIONIn patients with septic shock and kidney impairment on hospital admission, early albumin use may be associated with an increased composite outcome of RRT or in-hospital mortality. This increased risk is most associated with hyperoncotic rather than iso-oncotic albumin.
背景白蛋白输注对肾功能受损的脓毒性休克患者可能具有肾脏保护作用,也可能有害。研究问题脓毒性休克患者入院时肾功能受损,早期使用白蛋白是否能减轻其对肾脏替代治疗(RRT)的需求或院内死亡率。研究设计与方法这是一项回顾性、多中心、逆治疗概率加权队列研究,在全美 220 家不同地区的社区医院和教学医院进行。患者被分为住院期间接受白蛋白治疗(入院 24 小时内)或未接受白蛋白治疗的患者。结果 在纳入最终队列的 9988 名患者中,7929 人未接受白蛋白治疗,2059 人接受了白蛋白治疗。患者平均(标清)年龄为 67.8 岁(14.8),46.3% 为女性,入院当天平均(标清)eGFR 为 32(12)毫升/分钟/1.73 平方米。在加权队列中,33.8% 的患者未使用白蛋白,39.7% 的患者使用白蛋白后出现 RRT 或院内死亡的综合结果(OR 1.29,95% CI 1.14 - 1.47,P<0.001)。在入院时患有脓毒性休克和肾功能损害的患者中,早期使用白蛋白可能与 RRT 或院内死亡率的综合结果增加有关。这种风险的增加主要与高渗白蛋白而非等渗白蛋白有关。
{"title":"Comparative effectiveness of albumin versus no albumin on renal replacement therapy and mortality in patients with septic shock and renal impairment.","authors":"Asad E Patanwala,Alexander H Flannery,Hemalkumar B Mehta,Thomas E Hills,Colin J McArthur,Brian L Erstad","doi":"10.1016/j.chest.2024.10.012","DOIUrl":"https://doi.org/10.1016/j.chest.2024.10.012","url":null,"abstract":"BACKGROUNDAlbumin infusions may be renally protective or harmful in patients with septic shock who have kidney impairment. This can affect the need for renal replacement therapy (RRT) and in-hospital mortality.RESEARCH QUESTIONDoes the early use of albumin mitigate the need for RRT or in-hospital mortality in patients with septic shock and kidney impairment on hospital admission.STUDY DESIGN AND METHODSThis was a retrospective, multicenter, inverse probability-of-treatment weighted cohort study conducted in 220 geographically diverse community and teaching hospitals across the U.S. Adult patients were included if they had septic shock and kidney impairment on hospital admission. Patients were categorized as those who received albumin (within 24h of admission) or no albumin during hospitalization. Proportion of patients with RRT or in-hospital mortality were compared between groups.RESULTSOf the 9988 patients included in the final cohort, 7929 did not receive albumin and 2059 received albumin. Patients had a mean (SD) age of 67.8 years (14.8), 46.3% were female, and mean (SD) eGFR was 32 (12) ml/min/1.73m2 on the day of admission. In the weighted cohort, the composite outcome of RRT or in-hospital mortality occurred in 33.8% without albumin and 39.7% with albumin (OR 1.29, 95% CI 1.14 - 1.47, p<0.001). There was no significant difference with 5% albumin (OR 1.07, 95% CI 0.84 - 1.37), but there was a significantly increased risk with 25% albumin (OR 1.43, 95% CI 1.16 - 1.76).INTERPRETATIONIn patients with septic shock and kidney impairment on hospital admission, early albumin use may be associated with an increased composite outcome of RRT or in-hospital mortality. This increased risk is most associated with hyperoncotic rather than iso-oncotic albumin.","PeriodicalId":9782,"journal":{"name":"Chest","volume":"8 1","pages":""},"PeriodicalIF":9.6,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142451793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Conflicts of Interest in Bronchoscopy Research - Is Self-Reporting Sufficient? 支气管镜研究中的利益冲突--自我报告是否足够?
IF 9.6 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-10-17 DOI: 10.1016/j.chest.2024.10.006
Kaele M Leonard,Timothy A Khalil,Jacob Welch,Greta Dahlberg,Ankush Ratwani,Jennifer D Duke,Rafael Paez,Elisa J Gordon,Samira Shojaee,Robert J Lentz,Fabien Maldonado
BACKGROUNDRobotic assisted bronchoscopy has been enthusiastically adopted in the U.S. and transformed the management of patients with indeterminate pulmonary nodules. Unprecedented industry investments in research, development, and marketing have profoundly affected the bronchoscopy landscape, leading to concerns that conflicts of interest could influence the validity of bronchoscopy studies. Disclosures of conflicts of interest in research are predicated on open and transparent self-reporting.RESEARCH QUESTIONAre self-reported relevant conflicts of interest in articles pertaining to robotic assisted bronchoscopy accurate when compared to publicly available payments on the Centers of Medicare & Medicaid Services' Open Payments Database?STUDY DESIGN AND METHODSAll articles pertaining to robotic assisted bronchoscopy indexed on PubMed between 2016 and 2022 were screened for relevance. Articles appearing in the five journals with the most relevant publications were selected. General, research, and associated research payments reported in the Open Payments Database were recorded for each US physician-author with available data. "Relevant payments" refer to transactions made to authors by bronchoscopy-related companies. Documentation of all payments involving these companies during the three years prior to an article's submission date was obtained. These payments were compared to the self-reported conflicts of interest for each author, per article, and the number and value of payments were categorized and totaled.RESULTSTwenty-seven articles were included, accounting for 75 U.S. physicians with data reported in the Open Payments Database. Of the $17 million in relevant payments reported, $9.9 million were not disclosed (57%). Sixty-eight of 75 (91%) of authors had incomplete physician disclosures. Excluding food and beverage payments, sixty authors had incomplete disclosures (80%).INTERPRETATIONRelevant conflicts of interest appear to be inconsistently disclosed in publications on robotic assisted bronchoscopy, suggesting self-reporting may be an insufficient strategy. A centralized disclosure process that is automated or easier to use should be considered.
背景在美国,机器人辅助支气管镜已被广泛采用,并改变了对肺部结节患者的管理。业界在研究、开发和营销方面前所未有的投资深刻地影响了支气管镜检查的格局,导致人们担心利益冲突会影响支气管镜检查研究的有效性。研究问题与美国医疗保险与医疗补助服务中心(Centers of Medicare & Medicaid Services)公开支付数据库(Open Payments Database)中公开的支付情况相比,与机器人辅助支气管镜相关的文章中自我报告的相关利益冲突是否准确?研究设计与方法对2016年至2022年间PubMed上索引的所有与机器人辅助支气管镜相关的文章进行了相关性筛选。筛选出发表在相关性最高的五种期刊上的文章。记录了每位有数据的美国医生-作者在开放支付数据库(Open Payments Database)中报告的一般支付、研究支付和相关研究支付。"相关付款 "是指支气管镜相关公司向作者支付的交易。我们获得了文章提交日期前三年内涉及这些公司的所有付款文件。将这些付款与每篇文章中每位作者自我报告的利益冲突进行比较,并对付款的数量和价值进行分类和合计。结果共纳入了 27 篇文章,涉及 75 名在公开付款数据库中报告数据的美国医生。在报告的 1700 万美元相关付款中,有 990 万美元未披露(占 57%)。75 位作者中有 68 位(91%)的医生披露信息不完整。如果不包括餐饮费,则有 60 位作者披露的信息不完整(占 80%)。解释在有关机器人辅助支气管镜的出版物中,相关利益冲突的披露似乎并不一致,这表明自我报告可能是一种不充分的策略。应考虑采用自动化或更易于使用的集中披露流程。
{"title":"Conflicts of Interest in Bronchoscopy Research - Is Self-Reporting Sufficient?","authors":"Kaele M Leonard,Timothy A Khalil,Jacob Welch,Greta Dahlberg,Ankush Ratwani,Jennifer D Duke,Rafael Paez,Elisa J Gordon,Samira Shojaee,Robert J Lentz,Fabien Maldonado","doi":"10.1016/j.chest.2024.10.006","DOIUrl":"https://doi.org/10.1016/j.chest.2024.10.006","url":null,"abstract":"BACKGROUNDRobotic assisted bronchoscopy has been enthusiastically adopted in the U.S. and transformed the management of patients with indeterminate pulmonary nodules. Unprecedented industry investments in research, development, and marketing have profoundly affected the bronchoscopy landscape, leading to concerns that conflicts of interest could influence the validity of bronchoscopy studies. Disclosures of conflicts of interest in research are predicated on open and transparent self-reporting.RESEARCH QUESTIONAre self-reported relevant conflicts of interest in articles pertaining to robotic assisted bronchoscopy accurate when compared to publicly available payments on the Centers of Medicare & Medicaid Services' Open Payments Database?STUDY DESIGN AND METHODSAll articles pertaining to robotic assisted bronchoscopy indexed on PubMed between 2016 and 2022 were screened for relevance. Articles appearing in the five journals with the most relevant publications were selected. General, research, and associated research payments reported in the Open Payments Database were recorded for each US physician-author with available data. \"Relevant payments\" refer to transactions made to authors by bronchoscopy-related companies. Documentation of all payments involving these companies during the three years prior to an article's submission date was obtained. These payments were compared to the self-reported conflicts of interest for each author, per article, and the number and value of payments were categorized and totaled.RESULTSTwenty-seven articles were included, accounting for 75 U.S. physicians with data reported in the Open Payments Database. Of the $17 million in relevant payments reported, $9.9 million were not disclosed (57%). Sixty-eight of 75 (91%) of authors had incomplete physician disclosures. Excluding food and beverage payments, sixty authors had incomplete disclosures (80%).INTERPRETATIONRelevant conflicts of interest appear to be inconsistently disclosed in publications on robotic assisted bronchoscopy, suggesting self-reporting may be an insufficient strategy. A centralized disclosure process that is automated or easier to use should be considered.","PeriodicalId":9782,"journal":{"name":"Chest","volume":"8 1","pages":""},"PeriodicalIF":9.6,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142451802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Isolation of genetically distinct strains within the same species during treatment of MAC pulmonary disease. 在治疗 MAC 肺病的过程中,分离出同一物种中基因不同的菌株。
IF 9.6 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-10-17 DOI: 10.1016/j.chest.2024.10.010
Jiwon Lee,Su-Jin Park,Sangmi Kim,Han Na Lee,Heungsup Sung,Tae Sun Shim,Kyung-Wook Jo
BACKGROUNDResearch on isolating genetically different strains within the same species in patients undergoing treatment for Mycobacterium avium complex (MAC) pulmonary disease (PD) is limited. We investigated the frequency of genetically distinct strains identified within the same species among on-treatment isolates compared with pre-treatment isolates throughout the course of MAC-PD treatment.RESEARCH QUESTIONWhat is the frequency of genetically distinct strains identified within the same species among pre- and on-treatment isolates in patients with MAC-PD?STUDY DESIGN AND METHODSWe serially collected pre- and on-treatment clinical isolates from patients with MAC-PD treated for over one month from November 2019 to October 2022 at a tertiary hospital in South Korea. We utilized multilocus sequence typing (MLST) genotypic analysis to determine whether the on-treatment isolate was a genetically different strain compared with the pre-treatment isolate.RESULTSAmong 327 enrolled patients, we identified the on-treatment isolates of 198 patients as the same species as the pre-treatment isolates. The median treatment duration for the 198 patients was 14.4 months (interquartile range, 12.1-16.9 months). Of these patients, MLST analysis revealed the presence of a genetically different strain among the on-treatment isolates at least once in 24.7% (49/198) of patients (95% confidence interval, 18.9-31.4) compared to the pre-treatment isolate. There were variations in the timing, frequency, and number of distinct strains in these 49 patients.INTERPRETATIONWe identified a genetically distinct strain within the same species at least once in approximately 25% of patients in whom the same species was isolated after the initiation of anti-MAC-PD therapy. These findings may affect the determination of treatment outcomes and corresponding MAC-PD treatment strategies.
背景关于在接受复合分枝杆菌(MAC)肺病(PD)治疗的患者中分离出同一物种内不同基因菌株的研究十分有限。我们调查了在整个MAC-PD治疗过程中,与治疗前分离株相比,治疗中分离株与治疗前分离株在同一物种内鉴定出不同基因菌株的频率。我们利用多焦点序列分型(MLST)基因型分析来确定与治疗前的分离株相比,治疗中的分离株是否是基因不同的菌株。这 198 名患者的中位治疗时间为 14.4 个月(四分位间范围为 12.1-16.9 个月)。在这些患者中,MLST 分析显示,与治疗前的分离株相比,24.7% 的患者(49/198)(95% 置信区间,18.9-31.4)至少有一次在治疗中的分离株中发现了基因不同的菌株。在这 49 名患者中,不同菌株出现的时间、频率和数量存在差异。我们发现,在抗 MAC-PD 治疗开始后分离出相同菌株的患者中,约有 25% 的患者至少出现过一次同种菌株中基因不同的菌株。这些发现可能会影响治疗结果的确定和相应的 MAC-PD 治疗策略。
{"title":"Isolation of genetically distinct strains within the same species during treatment of MAC pulmonary disease.","authors":"Jiwon Lee,Su-Jin Park,Sangmi Kim,Han Na Lee,Heungsup Sung,Tae Sun Shim,Kyung-Wook Jo","doi":"10.1016/j.chest.2024.10.010","DOIUrl":"https://doi.org/10.1016/j.chest.2024.10.010","url":null,"abstract":"BACKGROUNDResearch on isolating genetically different strains within the same species in patients undergoing treatment for Mycobacterium avium complex (MAC) pulmonary disease (PD) is limited. We investigated the frequency of genetically distinct strains identified within the same species among on-treatment isolates compared with pre-treatment isolates throughout the course of MAC-PD treatment.RESEARCH QUESTIONWhat is the frequency of genetically distinct strains identified within the same species among pre- and on-treatment isolates in patients with MAC-PD?STUDY DESIGN AND METHODSWe serially collected pre- and on-treatment clinical isolates from patients with MAC-PD treated for over one month from November 2019 to October 2022 at a tertiary hospital in South Korea. We utilized multilocus sequence typing (MLST) genotypic analysis to determine whether the on-treatment isolate was a genetically different strain compared with the pre-treatment isolate.RESULTSAmong 327 enrolled patients, we identified the on-treatment isolates of 198 patients as the same species as the pre-treatment isolates. The median treatment duration for the 198 patients was 14.4 months (interquartile range, 12.1-16.9 months). Of these patients, MLST analysis revealed the presence of a genetically different strain among the on-treatment isolates at least once in 24.7% (49/198) of patients (95% confidence interval, 18.9-31.4) compared to the pre-treatment isolate. There were variations in the timing, frequency, and number of distinct strains in these 49 patients.INTERPRETATIONWe identified a genetically distinct strain within the same species at least once in approximately 25% of patients in whom the same species was isolated after the initiation of anti-MAC-PD therapy. These findings may affect the determination of treatment outcomes and corresponding MAC-PD treatment strategies.","PeriodicalId":9782,"journal":{"name":"Chest","volume":"44 1","pages":""},"PeriodicalIF":9.6,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142451798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editing approaches to treat Alpha-1 Antitrypsin Deficiency (AATD). 编辑治疗阿尔法-1 抗胰蛋白酶缺乏症(AATD)的方法。
IF 9.6 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-10-12 DOI: 10.1016/j.chest.2024.09.038
Derek M Erion,Liu Leah Y,Christopher R Brown,Stephen Rennard,Humam Farah
TOPIC IMPORTANCEAlpha-1 antitrypsin (AAT) deficiency (AATD) is a genetic disorder most commonly due to a single G to A point mutation, leading to debilitating lung and/or liver disorders and is associated with increased mortality. The E342K point mutation causes a conformational change of the AAT protein resulting in its retention in liver hepatocytes. This reduces AAT secretion into the serum resulting in higher protease activities due to the lack of inhibition from AAT, causing damage to healthy lung tissue. The current standard of care for lung manifestations involves weekly intravenous augmentation therapy and is considered sub-optimal for these patients. Furthermore, there is currently no approved treatment for liver manifestations. The unmet medical need for AATD patients remains high and new treatment options are needed to treat the underlying disease etiology.REVIEW FINDINGSAdvances in genomic medicines may enable treatment by editing the DNA or RNA sequence to produce wild-type AAT instead of the mutated AAT caused by the E342K mutation. One approach can be achieved by directing endogenous Adenosine Deaminases that act on RNA (ADARs) to the E342K RNA site, where they catalyze adenosine to inosine conversion through a process known as RNA editing. The A-I RNA change will be read as a G during protein translation, resulting in an altered amino acid and restoration of wild-type AAT secretion and function.SUMMARYIn this review, we will discuss the pathophysiology of AATD and emerging treatment options with particular focus on RNA editing as a disnd have stock options in ease-modifying treatment for both liver and lung disease.
主题重要性α-1 抗胰蛋白酶(AAT)缺乏症(AATD)是一种遗传性疾病,最常见的原因是单个 G 到 A 点突变,会导致衰弱的肺部和/或肝脏疾病,并与死亡率增加有关。E342K 点突变会导致 AAT 蛋白构象发生变化,从而使其滞留在肝脏肝细胞中。这减少了 AAT 向血清的分泌,导致蛋白酶活性因缺乏 AAT 的抑制而升高,从而对健康的肺组织造成损害。目前治疗肺部表现的标准疗法包括每周一次的静脉注射增强疗法,但对这些患者来说,这种疗法并不理想。此外,目前还没有针对肝脏表现的治疗方法获得批准。回顾性研究发现,基因组药物的进步可能会通过编辑 DNA 或 RNA 序列来产生野生型 AAT,而不是 E342K 突变所导致的变异 AAT,从而实现治疗。其中一种方法是将作用于 RNA 的内源性腺苷脱氨酶(ADARs)导向 E342K RNA 位点,通过 RNA 编辑催化腺苷向肌苷的转化。在蛋白质翻译过程中,A-I RNA 的变化将被读作 G,从而导致氨基酸的改变,并恢复野生型 AAT 的分泌和功能。摘要在本综述中,我们将讨论 AATD 的病理生理学和新出现的治疗方案,并特别关注 RNA 编辑作为肝脏和肺部疾病的易变治疗方法。
{"title":"Editing approaches to treat Alpha-1 Antitrypsin Deficiency (AATD).","authors":"Derek M Erion,Liu Leah Y,Christopher R Brown,Stephen Rennard,Humam Farah","doi":"10.1016/j.chest.2024.09.038","DOIUrl":"https://doi.org/10.1016/j.chest.2024.09.038","url":null,"abstract":"TOPIC IMPORTANCEAlpha-1 antitrypsin (AAT) deficiency (AATD) is a genetic disorder most commonly due to a single G to A point mutation, leading to debilitating lung and/or liver disorders and is associated with increased mortality. The E342K point mutation causes a conformational change of the AAT protein resulting in its retention in liver hepatocytes. This reduces AAT secretion into the serum resulting in higher protease activities due to the lack of inhibition from AAT, causing damage to healthy lung tissue. The current standard of care for lung manifestations involves weekly intravenous augmentation therapy and is considered sub-optimal for these patients. Furthermore, there is currently no approved treatment for liver manifestations. The unmet medical need for AATD patients remains high and new treatment options are needed to treat the underlying disease etiology.REVIEW FINDINGSAdvances in genomic medicines may enable treatment by editing the DNA or RNA sequence to produce wild-type AAT instead of the mutated AAT caused by the E342K mutation. One approach can be achieved by directing endogenous Adenosine Deaminases that act on RNA (ADARs) to the E342K RNA site, where they catalyze adenosine to inosine conversion through a process known as RNA editing. The A-I RNA change will be read as a G during protein translation, resulting in an altered amino acid and restoration of wild-type AAT secretion and function.SUMMARYIn this review, we will discuss the pathophysiology of AATD and emerging treatment options with particular focus on RNA editing as a disnd have stock options in ease-modifying treatment for both liver and lung disease.","PeriodicalId":9782,"journal":{"name":"Chest","volume":"11 1","pages":""},"PeriodicalIF":9.6,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142439435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interstitial Lung Abnormality: Narrative Review of the Approach to Diagnosis and Management. 肺间质异常:诊断和管理方法的叙述性回顾。
IF 9.5 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-10-10 DOI: 10.1016/j.chest.2024.09.033
Zein Kattih, Brett Bade, Hiroto Hatabu, Kevin Brown, Joseph Parambil, Akinori Hata, Peter J Mazzone, Stephen Machnicki, Dominick Guerrero, Muhammad Qasim Chaudhry, Liz Kellermeyer, Kaitlin Johnson, Stuart Cohen, Ramona Ramdeo, Jason Naidich, Alain Borczuck, Suhail Raoof

Topic importance: As interstitial lung abnormalities (ILAs) are increasingly recognized on imaging and in clinical practice, identification and appropriate management are critical. We propose an algorithmic approach to the identification and management of patients with ILAs.

Review findings: The radiologist initially identifies chest CT scan findings suggestive of an ILA pattern and excludes findings that are not consistent with ILAs. The next step is to confirm that these findings occupy > 5% of a nondependent lung zone. At this point, the radiologic pattern of ILA is identified. These findings are classified as non-subpleural, subpleural nonfibrotic, and subpleural fibrotic. It is then incumbent on the clinician to ascertain if the patient has symptoms and/or abnormal pulmonary physiology that may be attributable to these radiologic changes. Based on the patient's symptoms, physiological assessment, and risk factors for interstitial lung disease (ILD), we recommend classifying patients as having ILA, at high risk for developing ILD, probable ILD, or ILD. In patients identified as having ILA, a multidisciplinary discussion should evaluate features that indicate an increased risk of progression. If these features are present, serial monitoring is recommended to be proactive. If the patient does not have imaging or clinical features that indicate an increased risk of progression, then monitoring is recommended to be reactive. If ILD is subsequently diagnosed, the management is disease specific.

Summary: We anticipate this algorithmic approach will aid clinicians in interpreting the radiologic pattern described as ILA within the clinical context of their patients.

主题的重要性:随着肺间质异常(ILAs)在影像学和临床实践中被越来越多地认识到,识别和适当的管理至关重要。我们提出了一种识别和处理 ILAs 患者的算法方法:放射科医生首先确定提示 ILA 模式的胸部 CT 扫描结果,并排除不符合 ILA 的结果。下一步是确认这些发现占非独立肺区的比例大于 5%。至此,ILA 的放射学模式就确定了。这些发现可分为非胸膜下、胸膜下非纤维化和胸膜下纤维化。然后,临床医生有责任确定患者是否因这些放射学改变而出现症状和/或肺部生理异常。根据患者的症状、生理评估和间质性肺病(ILD)的危险因素,我们建议将患者分为 ILA、ILD 高危人群、可能 ILD 或 ILD。对于已确定患有 ILA 的患者,应通过多学科讨论评估表明病情恶化风险增加的特征。如果存在这些特征,建议进行连续监测,以未雨绸缪。如果患者没有影像学或临床特征表明病情恶化的风险增加,则建议进行反应性监测。总结:我们预计这种算法将有助于临床医生在患者的临床背景下解释被描述为 ILA 的放射学模式。
{"title":"Interstitial Lung Abnormality: Narrative Review of the Approach to Diagnosis and Management.","authors":"Zein Kattih, Brett Bade, Hiroto Hatabu, Kevin Brown, Joseph Parambil, Akinori Hata, Peter J Mazzone, Stephen Machnicki, Dominick Guerrero, Muhammad Qasim Chaudhry, Liz Kellermeyer, Kaitlin Johnson, Stuart Cohen, Ramona Ramdeo, Jason Naidich, Alain Borczuck, Suhail Raoof","doi":"10.1016/j.chest.2024.09.033","DOIUrl":"10.1016/j.chest.2024.09.033","url":null,"abstract":"<p><strong>Topic importance: </strong>As interstitial lung abnormalities (ILAs) are increasingly recognized on imaging and in clinical practice, identification and appropriate management are critical. We propose an algorithmic approach to the identification and management of patients with ILAs.</p><p><strong>Review findings: </strong>The radiologist initially identifies chest CT scan findings suggestive of an ILA pattern and excludes findings that are not consistent with ILAs. The next step is to confirm that these findings occupy > 5% of a nondependent lung zone. At this point, the radiologic pattern of ILA is identified. These findings are classified as non-subpleural, subpleural nonfibrotic, and subpleural fibrotic. It is then incumbent on the clinician to ascertain if the patient has symptoms and/or abnormal pulmonary physiology that may be attributable to these radiologic changes. Based on the patient's symptoms, physiological assessment, and risk factors for interstitial lung disease (ILD), we recommend classifying patients as having ILA, at high risk for developing ILD, probable ILD, or ILD. In patients identified as having ILA, a multidisciplinary discussion should evaluate features that indicate an increased risk of progression. If these features are present, serial monitoring is recommended to be proactive. If the patient does not have imaging or clinical features that indicate an increased risk of progression, then monitoring is recommended to be reactive. If ILD is subsequently diagnosed, the management is disease specific.</p><p><strong>Summary: </strong>We anticipate this algorithmic approach will aid clinicians in interpreting the radiologic pattern described as ILA within the clinical context of their patients.</p>","PeriodicalId":9782,"journal":{"name":"Chest","volume":" ","pages":""},"PeriodicalIF":9.5,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142406173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Peak Inspiratory Flow and Inhaler Prescription Strategies in a Specialized COPD Clinical Program: A Real-World Observational Study. 专业慢性阻塞性肺病临床项目中的峰值吸入流量和吸入器处方策略:真实世界观察研究
IF 9.5 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-10-09 DOI: 10.1016/j.chest.2024.09.031
Sarah Pankovitch, Michael Frohlich, Bader AlOthman, Jeffrey Marciniuk, Joanie Bernier, Dorcas Paul-Emile, Jean Bourbeau, Bryan A Ross

Background: COPD inhaler regimens should be appropriate for the patient's peak inspiratory flow (PIF) and should ideally consist of single or similar device(s).

Research questions: In a subspecialized COPD clinic: (1) What is the prevalence of patients with suboptimal PIF and with inappropriate device(s) for measured PIF? (2) Are there patient-related risk factors associated with suboptimal PIF? (3) What is the prevalence of patients with non-single inhaler therapy (SIT)/nonsimilar devices? (4) Does point-of-care PIF affect clinical decision-making?

Study design and methods: In this single-center real-world observational study, PIF was measured systematically at every outpatient visit in a subspecialized COPD clinic, and point-of-care results were provided to the clinician. Coprimary outcomes were the prevalence of outpatients with suboptimal PIF and with inappropriate devices for measured PIF. Secondary outcomes were patient-related risk factors associated with suboptimal PIF, the prevalence of non-SIT/nonsimilar devices, the prevalence of regimens consisting of either inappropriate device(s) for measured PIF and/or non-SIT/nonsimilar devices, and the effect of point-of-care PIF on clinical decision-making.

Results: Suboptimal PIF was identified in 45 of 161 participants (28%), and inappropriate device(s) for measured PIF were identified in 18 participants (11.2%). Significant associations were observed between suboptimal PIF and age (1.09; 95% CI, 1.04-1.15), female sex (10.30; 95% CI, 4.45-27.10), height (0.92; 95% CI, 0.88-0.96), BMI (0.90; 95% CI, 0.84-0.96), and FEV1 (0.09; 95% CI, 0.03-0.26). After adjustment for age and sex, the association between suboptimal PIF and BMI, but not height, remained significant. Non-SIT and/or nonsimilar devices were identified in 50 participants (31.1%). Regimens consisting of either inappropriate device(s) for measured PIF and/or non-SIT/nonsimilar devices were observed in 59 participants (36.6%). Inhaler prescription changes were observed in this latter group (3.39; 95% CI, 1.76-6.64), as well as in patients with suboptimal PIF who already had SIT/similar regimens (2.93; 95% CI, 1.07-7.92).

Interpretation: Suboptimal PIF and inappropriate devices for measured PIF are highly prevalent among outpatients from a subspecialized COPD clinic. Female sex, reduced FEV1, and low BMI are important, readily identifiable risk factors for suboptimal PIF, and point-of-care PIF can inform clinical decision-making.

背景:慢性阻塞性肺病吸入器治疗方案应与患者的吸气峰值流量(PIF)相适应,最好由单一或类似装置组成:研究问题:在慢性阻塞性肺疾病亚专科门诊中:研究问题:在慢性阻塞性肺疾病专科门诊中:1:PIF 不达标和使用不合适的设备测量 PIF 的患者比例是多少?2:是否存在与患者相关的风险因素导致 PIF 不达标?3: 使用非单一吸入器疗法(SIT)/非类似设备的患者比例是多少?4:护理点 PIF 是否会影响临床决策?在这项单中心真实世界观察性研究中,慢性阻塞性肺疾病亚专科门诊在每次门诊时都会对 PIF 进行系统测量,并向临床医生提供护理点结果。共同主要结果是门诊患者中 PIF 不达标和使用不适当设备测量 PIF 的比例。次要结果是与次优 PIF 相关的患者相关风险因素、非 SIT/非相似设备的患病率、由用于测量 PIF 的不适当设备和/或非 SIT/非相似设备组成的治疗方案的患病率,以及护理点 PIF 对临床决策的影响:结果:161 名参与者中有 45 人(28%)发现了 PIF 不达标,18 人(11.2%)发现了用于测量 PIF 的不适当设备。观察发现,PIF 不达标与年龄(1.09 [1.04,1.15])、女性性别(10.30 [4.45,27.10])、身高(0.92 [0.88,0.96])、体重指数(0.90 [0.84,0.96])和 FEV1(0.09 [0.03,0.26])之间存在显著关联。在对年龄和性别进行调整后,次优 PIF 与体重指数(BMI)(而非身高)之间的关系仍然显著。有 50 名参与者(31.1%)发现了非 SIT 和/或非类似装置。59名参与者(36.6%)的治疗方案中使用了不适合测量PIF的设备和/或非SIT/非类似设备。在后一组患者(3.39 [1.76,6.64])以及已使用 SIT/类似方案的 PIF 不达标的患者(2.93 [1.07,7.92])中观察到了吸入器处方的变化:在慢性阻塞性肺疾病专科门诊的门诊患者中,PIF不达标和测量PIF的设备不合适的情况非常普遍。女性性别、FEV1降低和低体重指数是导致PIF不达标的重要且易于识别的风险因素,而护理点PIF可为临床决策提供依据。
{"title":"Peak Inspiratory Flow and Inhaler Prescription Strategies in a Specialized COPD Clinical Program: A Real-World Observational Study.","authors":"Sarah Pankovitch, Michael Frohlich, Bader AlOthman, Jeffrey Marciniuk, Joanie Bernier, Dorcas Paul-Emile, Jean Bourbeau, Bryan A Ross","doi":"10.1016/j.chest.2024.09.031","DOIUrl":"10.1016/j.chest.2024.09.031","url":null,"abstract":"<p><strong>Background: </strong>COPD inhaler regimens should be appropriate for the patient's peak inspiratory flow (PIF) and should ideally consist of single or similar device(s).</p><p><strong>Research questions: </strong>In a subspecialized COPD clinic: (1) What is the prevalence of patients with suboptimal PIF and with inappropriate device(s) for measured PIF? (2) Are there patient-related risk factors associated with suboptimal PIF? (3) What is the prevalence of patients with non-single inhaler therapy (SIT)/nonsimilar devices? (4) Does point-of-care PIF affect clinical decision-making?</p><p><strong>Study design and methods: </strong>In this single-center real-world observational study, PIF was measured systematically at every outpatient visit in a subspecialized COPD clinic, and point-of-care results were provided to the clinician. Coprimary outcomes were the prevalence of outpatients with suboptimal PIF and with inappropriate devices for measured PIF. Secondary outcomes were patient-related risk factors associated with suboptimal PIF, the prevalence of non-SIT/nonsimilar devices, the prevalence of regimens consisting of either inappropriate device(s) for measured PIF and/or non-SIT/nonsimilar devices, and the effect of point-of-care PIF on clinical decision-making.</p><p><strong>Results: </strong>Suboptimal PIF was identified in 45 of 161 participants (28%), and inappropriate device(s) for measured PIF were identified in 18 participants (11.2%). Significant associations were observed between suboptimal PIF and age (1.09; 95% CI, 1.04-1.15), female sex (10.30; 95% CI, 4.45-27.10), height (0.92; 95% CI, 0.88-0.96), BMI (0.90; 95% CI, 0.84-0.96), and FEV<sub>1</sub> (0.09; 95% CI, 0.03-0.26). After adjustment for age and sex, the association between suboptimal PIF and BMI, but not height, remained significant. Non-SIT and/or nonsimilar devices were identified in 50 participants (31.1%). Regimens consisting of either inappropriate device(s) for measured PIF and/or non-SIT/nonsimilar devices were observed in 59 participants (36.6%). Inhaler prescription changes were observed in this latter group (3.39; 95% CI, 1.76-6.64), as well as in patients with suboptimal PIF who already had SIT/similar regimens (2.93; 95% CI, 1.07-7.92).</p><p><strong>Interpretation: </strong>Suboptimal PIF and inappropriate devices for measured PIF are highly prevalent among outpatients from a subspecialized COPD clinic. Female sex, reduced FEV<sub>1</sub>, and low BMI are important, readily identifiable risk factors for suboptimal PIF, and point-of-care PIF can inform clinical decision-making.</p>","PeriodicalId":9782,"journal":{"name":"Chest","volume":" ","pages":""},"PeriodicalIF":9.5,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gender Differences in Outcomes of Ambulatory and Hospitalized Patients With Obesity Hypoventilation Syndrome. 肥胖换气不足综合征门诊和住院病人治疗效果的性别差异。
IF 9.5 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-10-09 DOI: 10.1016/j.chest.2024.10.002
Nathan C Nowalk, Babak Mokhlesi, Julie M Neborak, Juan Fernando Masa Jimenez, Ivan Benitez, Francisco J Gomez de Terreros, Auxiliadora Romero, Candela Caballero-Eraso, Maria F Troncoso, Mónica González, Soledad López-Martín, José M Marin, Sergi Martí, Trinidad Díaz-Cambriles, Eusebi Chiner, Carlos Egea, Isabel Utrabo, Ferran Barbe, Maria Ángeles Sánchez-Quiroga

Background: Obesity hypoventilation syndrome (OHS) is associated with high morbidity and mortality. There are few data on whether there are gender differences in outcomes.

Research question: Is female gender associated with worse outcomes in ambulatory and hospitalized patients with OHS?

Study design and methods: Post hoc analyses were performed on 2 separate OHS cohorts: (1) stable ambulatory patients from the 2 Pickwick randomized controlled trials; and (2) hospitalized patients with acute-on-chronic hypercapnic respiratory failure from a retrospective international cohort. We first conducted bivariate analyses of baseline characteristics and therapeutics between genders. Variables of interest from these analyses were then grouped into linear mixed effects models, Cox proportional hazards models, or logistic regression models to assess the association of gender on various clinical outcomes.

Results: The ambulatory prospective cohort included 300 patients (64% female), and the hospitalized retrospective cohort included 1,162 patients (58% female). For both cohorts, women were significantly older and more obese than men. Compared with men, baseline Paco2 was similar in ambulatory patients but higher in hospitalized women. In the ambulatory cohort, in unadjusted analysis, women had increased risk of emergency department visits. However, gender was not associated with the composite outcome of emergency department visit, hospitalization, or all-cause mortality in the fully adjusted model. In the hospitalized cohort, prescription of positive airway pressure was less prevalent in women at discharge. In unadjusted analysis, hospitalized women had a higher mortality at 3, 6, and 12 months following hospital discharge compared with men. However, after adjusting for age, gender was not associated with mortality.

Interpretation: Although the diagnosis of OHS is established at a more advanced age in women, gender is not independently associated with worse clinical outcomes after adjusting for age. Future studies are needed to examine gender-related health disparities in diagnosis and treatment of OHS.

背景:肥胖低通气综合征(OHS)与高发病率和高死亡率有关。关于预后是否存在性别差异的数据很少。研究问题:女性是否与肥胖低通气综合征门诊和住院患者较差的预后有关?我们对两组不同的 OHS 患者进行了事后分析:1)来自两项皮克维克随机对照试验的稳定的非卧床患者;2)来自一项回顾性国际队列的急性-慢性高碳酸血症呼吸衰竭住院患者。我们首先对不同性别的基线特征和治疗方法进行了双变量分析。然后将这些分析中的相关变量分组到线性混合效应模型、Cox 比例危险模型或逻辑回归模型中,以评估性别与各种临床结果的关系:流动前瞻性队列包括 300 名患者(64% 为女性),住院回顾性队列包括 1 162 名患者(58% 为女性)。在这两个队列中,女性的年龄和肥胖程度都明显高于男性。与男性相比,非住院患者的基线 PaCO2 与男性相似,但住院女性的基线 PaCO2 较高。在门诊队列中,未经调整的分析显示,女性看急诊的风险更高。然而,在完全调整模型中,性别与急诊就诊、住院或全因死亡率的综合结果无关。在住院患者队列中,女性出院时较少使用气道正压(PAP)处方。在未经调整的分析中,与男性相比,住院女性在出院后 3、6 和 12 个月的死亡率较高。然而,在对年龄进行调整后,性别与死亡率无关:解释:虽然女性确诊 OHS 的年龄较高,但在调整年龄因素后,性别与较差的临床结果并无独立关联。今后还需要开展研究,探讨在诊断和治疗 OHS 方面与性别相关的健康差异。
{"title":"Gender Differences in Outcomes of Ambulatory and Hospitalized Patients With Obesity Hypoventilation Syndrome.","authors":"Nathan C Nowalk, Babak Mokhlesi, Julie M Neborak, Juan Fernando Masa Jimenez, Ivan Benitez, Francisco J Gomez de Terreros, Auxiliadora Romero, Candela Caballero-Eraso, Maria F Troncoso, Mónica González, Soledad López-Martín, José M Marin, Sergi Martí, Trinidad Díaz-Cambriles, Eusebi Chiner, Carlos Egea, Isabel Utrabo, Ferran Barbe, Maria Ángeles Sánchez-Quiroga","doi":"10.1016/j.chest.2024.10.002","DOIUrl":"10.1016/j.chest.2024.10.002","url":null,"abstract":"<p><strong>Background: </strong>Obesity hypoventilation syndrome (OHS) is associated with high morbidity and mortality. There are few data on whether there are gender differences in outcomes.</p><p><strong>Research question: </strong>Is female gender associated with worse outcomes in ambulatory and hospitalized patients with OHS?</p><p><strong>Study design and methods: </strong>Post hoc analyses were performed on 2 separate OHS cohorts: (1) stable ambulatory patients from the 2 Pickwick randomized controlled trials; and (2) hospitalized patients with acute-on-chronic hypercapnic respiratory failure from a retrospective international cohort. We first conducted bivariate analyses of baseline characteristics and therapeutics between genders. Variables of interest from these analyses were then grouped into linear mixed effects models, Cox proportional hazards models, or logistic regression models to assess the association of gender on various clinical outcomes.</p><p><strong>Results: </strong>The ambulatory prospective cohort included 300 patients (64% female), and the hospitalized retrospective cohort included 1,162 patients (58% female). For both cohorts, women were significantly older and more obese than men. Compared with men, baseline Paco<sub>2</sub> was similar in ambulatory patients but higher in hospitalized women. In the ambulatory cohort, in unadjusted analysis, women had increased risk of emergency department visits. However, gender was not associated with the composite outcome of emergency department visit, hospitalization, or all-cause mortality in the fully adjusted model. In the hospitalized cohort, prescription of positive airway pressure was less prevalent in women at discharge. In unadjusted analysis, hospitalized women had a higher mortality at 3, 6, and 12 months following hospital discharge compared with men. However, after adjusting for age, gender was not associated with mortality.</p><p><strong>Interpretation: </strong>Although the diagnosis of OHS is established at a more advanced age in women, gender is not independently associated with worse clinical outcomes after adjusting for age. Future studies are needed to examine gender-related health disparities in diagnosis and treatment of OHS.</p>","PeriodicalId":9782,"journal":{"name":"Chest","volume":" ","pages":""},"PeriodicalIF":9.5,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Chest
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1